An AI model that uses machine learning to try to pick stocks is optimistic about the prospects for some stocks in volatile sectors over the coming month. iFi AI is a company that targets retail investors by combining fundamental, technical and news data to identify stocks that could potentially rise. The company’s model uses IBM’s Watsonx. The model had a big payoff this week when Marathon Oil, one of iFi AI’s favorite stocks as of May 20, inked a deal to be acquired by ConocoPhillips. After the news broke, the company’s shares rose more than 8% in one trading session. The stock that the model has the highest confidence in and is expected to rise the most is the similarly named Marathon Digital. However, Marathon Digital is not an energy company, it’s a bitcoin miner. The company’s stock is down about 17% in 2024 after a big rise last year, but iFi AI expects it to rise more than 40% from Thursday’s closing price. Below are the top five stocks from iFi AI’s most trusted category with a market capitalization of at least $1 billion over the next 30 days. Another struggling stock on the list is Kilroy Realty, whose shares have fallen nearly 16% this year. The stock is also iFi AI’s top overall pick as of Friday morning. Kilroy is a real estate investment trust that owns office, life sciences and mixed-use buildings, with the majority of its holdings in California. Office real estate in particular has been an area of concern recently, but Kilroy has recently taken steps to shore up its balance sheet, including raising $400 million through a bond sale. The company said in its quarterly report that it had $2 billion in liquidity at the end of March. Other stocks with high confidence and big upside potential are a trio of biotech stocks: Bridge Biopharma, Viking Therapeutics and Protagonist Therapeutics. Small biotech and pharmaceutical stocks are notoriously volatile, as a news update on just one drug or treatment can cause a big change in a company’s outlook. Viking is the largest of these three, with a market capitalization of just under $7 billion. The company develops an oral anti-obesity drug. Ron Insana, a senior analyst and commentator at CNBC, is CEO of iFi AI, which was founded in March.
AI model predicts these stocks will rise the most in the coming month
Services
© 2026 Business Investopedia. All Rights Reserved.